Skip to main content

Advertisement

Contact Yihebali Chi

From: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Contact corresponding author